In the pursuit of market outperformance, investors navigate the landscape of stock selection. The right picks can play a pivotal role in enhancing your wealth.
The closing price of Candel Therapeutics Inc (NASDAQ: CADL) was $5.44 for the day, down -3.72% from the previous closing price of $5.65. In other words, the price has decreased by -$3.72 from its previous closing price. On the day, 0.65 million shares were traded. CADL stock price reached its highest trading level at $5.7771 during the session, while it also had its lowest trading level at $5.345.
Ratios:
Our analysis of CADL’s different ratios will help us gain a deeper understanding of the company. For the most recent quarter (mrq), Quick Ratio is recorded 8.25 and its Current Ratio is at 8.25. In the meantime, Its Debt-to-Equity ratio is 0.09 whereas as Long-Term Debt/Eq ratio is at 0.03.
Upgrades & Downgrades
In the most recent recommendation for this company, Stephens on October 28, 2025, initiated with a Overweight rating and assigned the stock a target price of $15.
On September 03, 2025, BofA Securities Downgraded its rating to Neutral which previously was Buy but kept the price unchanged to $7.
Insider Transactions:
Also, insider trades can serve as a great indicator of what management thinks about the future direction of a stock’s price. A recent insider transaction in this stock occurred on Jul 28 ’25 when Nichols William Garrett sold 937 shares for $6.98 per share. The transaction valued at 6,540 led to the insider holds 52,493 shares of the business.
Nichols William Garrett sold 781 shares of CADL for $3,936 on Jun 30 ’25. The Chief Medical Officer now owns 52,493 shares after completing the transaction at $5.04 per share. On Jun 30 ’25, another insider, WILLIAM GARRETT NICHOLS, who serves as the Officer of the company, bought 3,593 shares for $4.90 each.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, CADL now has a Market Capitalization of 298646784 and an Enterprise Value of 218890768.
Stock Price History:
The Beta on a monthly basis for CADL is -0.93, which has changed by -0.37471265 over the last 52 weeks, in comparison to a change of 0.14778805 over the same period for the S&P500. Over the past 52 weeks, CADL has reached a high of $13.68, while it has fallen to a 52-week low of $4.25. The 50-Day Moving Average of the stock is 3.39%, while the 200-Day Moving Average is calculated to be -1.70%.
Shares Statistics:
CADL traded an average of 826.73K shares per day over the past three months and 632060 shares per day over the past ten days. A total of 54.90M shares are outstanding, with a floating share count of 41.06M. Insiders hold about 25.21% of the company’s shares, while institutions hold 36.97% stake in the company. Shares short for CADL as of 1765756800 were 8327222 with a Short Ratio of 10.07, compared to 1763078400 on 8344526. Therefore, it implies a Short% of Shares Outstanding of 8327222 and a Short% of Float of 19.16.
Earnings Estimates
. The current rating of Candel Therapeutics Inc (CADL) is the result of assessments by 2.0 analysts actively engaged in evaluating its market dynamics.The consensus estimate for the next quarter is -$0.21, with high estimates of -$0.17 and low estimates of -$0.25.
Analysts are recommending an EPS of between -$0.41 and -$0.8 for the fiscal current year, implying an average EPS of -$0.61. EPS for the following year is -$0.5, with 1.0 analysts recommending between -$0.5 and -$0.5.
